Bladder / Urothelial
OPEN TO ENROLLMENT
1. IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy
This study is to evaluate the efficacy and safety of adjuvant treatment with MPDL3280A, an anti-programmed death-ligand 1 (PD-L1) antibody, compared with observation in participants with PD-L1-selected muscle-invasive bladder cancer (MIBC) who are at high risk for recurrence following cystectomy.
2. A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.